Latest News and Press Releases

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leader in brain–computer interface (BCI) technology, today announced that it has received 510(k)...

New York City, April 16, 2025 (GLOBE NEWSWIRE) -- Introduction: Unlocking Brain Power in the Modern Age In the hyper-digital world of 2025, it's no surprise that more and more people are silently...

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A

– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation...

Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein...

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients...

Los Angeles, CA, March 19, 2025 (GLOBE NEWSWIRE) -- ANEUVO, a leader in non-invasive therapy development, has announced the launch of the ASPIRE™ Home Study, the next phase of clinical research for...

MINNEAPOLIS, March 19, 2025 (GLOBE NEWSWIRE) -- Major depression impacts more than 5 million U.S. adolescents every year, and NIH data shows that 20% of those aged 12 to 16 have had at least one...

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – –...